UK-based gene and cell therapy group Oxford Biomedica has sold its Windrush Court facility in Oxford to Kadans Science Partner for £60 mln (€68 mln).
UK-based gene and cell therapy group Oxford Biomedica has sold its Windrush Court facility in Oxford to Kadans Science Partner for £60 mln (€68 mln).
Frankfurt-based fund manager Habona Invest has acquired two retail parks in the Bavarian cities of Passau and Kirchseeon from the Küblböck Group for around €26 mln.